Literature DB >> 25902480

Regulatory B cells: origin, phenotype, and function.

Elizabeth C Rosser1, Claudia Mauri2.   

Abstract

Regulatory B (Breg) cells are immunosuppressive cells that support immunological tolerance. Through the production of interleukin-10 (IL-10), IL-35, and transforming growth factor β (TGF-β), Breg cells suppress immunopathology by prohibiting the expansion of pathogenic T cells and other pro-inflammatory lymphocytes. Recent work has shown that different inflammatory environments induce distinct Breg cell populations. Although these findings highlight the relevance of inflammatory signals in the differentiation of Breg cells, they also raise other questions about Breg cell biology and phenotype. For example, what are the functional properties and phenotype of Breg cells? Can a Breg cell arise at every stage in B cell development? Is inflammation the primary requisite for Breg cell differentiation? Here, we use these questions to discuss the advances in understanding Breg cell biology, with a particular emphasis on their ontogeny; we propose that multiple Breg cell subsets can be induced in response to inflammation at different stages in development.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25902480     DOI: 10.1016/j.immuni.2015.04.005

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  412 in total

1.  Regulatory T and B lymphocytes in a spontaneous autoimmune polyneuropathy.

Authors:  S Quan; J R Sheng; P M Abraham; B Soliven
Journal:  Clin Exp Immunol       Date:  2016-02-04       Impact factor: 4.330

2.  IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.

Authors:  Anushruti Sarvaria; Rafet Basar; Rohtesh S Mehta; Hila Shaim; Muharrem Muftuoglu; Ahmad Khoder; Takuye Sekine; Elif Gokdemir; Kayo Kondo; David Marin; May Daher; Amin M Alousi; Abdullah Alsuliman; Enli Liu; Betul Oran; Amanda Olson; Roy B Jones; Uday Popat; Chitra Hosing; Richard Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-07-20       Impact factor: 22.113

Review 3.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 4.  Regulatory B cells in experimental stroke.

Authors:  Hilary A Seifert; Arthur A Vandenbark; Halina Offner
Journal:  Immunology       Date:  2018-02-05       Impact factor: 7.397

5.  IL-37- and IL-35/IL-37-Producing Plasma Cells in Chronic Periodontitis.

Authors:  L Jing; S Kim; L Sun; L Wang; E Mildner; K Divaris; Y Jiao; S Offenbacher
Journal:  J Dent Res       Date:  2019-05-03       Impact factor: 6.116

6.  H.pylori Infection Alleviates Acute and Chronic Colitis with the Expansion of Regulatory B Cells in Mice.

Authors:  Xia Li; Jiang Tan; Feng Zhang; Qian Xue; Ning Wang; Xu Cong; Jingtong Wang
Journal:  Inflammation       Date:  2019-10       Impact factor: 4.092

Review 7.  Tolerance in the Age of Immunotherapy.

Authors:  Jeffrey A Bluestone; Mark Anderson
Journal:  N Engl J Med       Date:  2020-09-17       Impact factor: 91.245

Review 8.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

9.  Frequency and immunophenotype of IL10-producing regulatory B cells in optic neuritis.

Authors:  Sara Lundqvist; Signe Modvig; Emilie A Fischer; Jette L Frederiksen; Matilda Degn
Journal:  Immunology       Date:  2018-12-27       Impact factor: 7.397

10.  Altered B Cell Homeostasis in Patients with Major Depressive Disorder and Normalization of CD5 Surface Expression on Regulatory B Cells in Treatment Responders.

Authors:  Diana Ahmetspahic; Kathrin Schwarte; Oliver Ambrée; Christian Bürger; Vladislava Falcone; Katharina Seiler; Mehrdad Rahbar Kooybaran; Laura Grosse; Fernand Roos; Julia Scheffer; Silke Jörgens; Katja Koelkebeck; Udo Dannlowski; Volker Arolt; Stefanie Scheu; Judith Alferink
Journal:  J Neuroimmune Pharmacol       Date:  2017-09-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.